| Akronym |
Victorion-2-Prevent |
| Syfte |
En randomiserad, dubbelblind, placebokontrollerad multicenterstudie som utvärderar effekten av inclisiran på allvarliga kardiovaskulära händelser hos deltagare med etablerad kardiovaskulärsjukdom (VICTORION-2 PREVENT) |
| Urvalskriterier |
Participants eligible for inclusion in this study must fulfill all of the following criteria: Male or female ≥ 40 years of age. Fasting LDL-C ≥ 1.8 mmol/L at screening visit. At the screening visit, participants must be on a stable (≥ 4 weeks) and well-tolerated lipid-lowering regimen (including e. g. with or without Ezetimibe) that must include a high-intensity statin therapy either atorvastatin ≥ 40 mg QD or rosuvastatin ≥ 20 mg QD. Established CV disease defined as any of following: Previous myocardial infarction, Previous ischemic stroke, Symptomatic peripheral arterial disease (PAD) as evidenced by either intermittent claudication with ABI <0.85, prior arterial revascularization procedure or amputation due to atherosclerotic disease. |
| Sökord |
Victorion-2-Prevent, Blodfetter, Blodfettssänkande, läkemedelsstudie |
| Tema/Funktion, Medicinsk Enhet |
Tema Hjärta, Kärl och Neuro, ME Kärlkirurgi |
